UNSPSC 51172134: Flopropione

This classification denotes an antispasmotic agent with the molecular formula C9H10O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 05V5NVB5Y1, chemically known as 2,4,6-trihydroxypropiophenone but generally known as flopropione, which bears US NIH Compound Identifier 3362. European Medicines Agency schedules Flopropione in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07647MIG.

UNSPSC 51172134 Flopropione, a Commodity code, represents pharmaceutical and chemical testing products and services procured by state and local government agencies for criminal justice, health and human services, and cooperative purchasing operations. The recent activity under this code centers on specimen collection, drug testing services, prescription fulfillment programs, and multi-source generic pharmaceutical supply chains. State and local buying entities include county criminal justice departments, state health and human services commissions, and multistate cooperative purchasing alliances serving facilities across multiple jurisdictions. The scope encompasses laboratory testing services (immunoassay screening with confirmatory testing via LC/MS/MS or GC/MS, alternative methodologies including oral fluid and hair testing), Interactive Voice Response systems for test notifications, certified lab operations meeting SAMHSA and state licensure standards, and supply agreements for generic and OTC pharmaceuticals with compliance to cGMP and Drug Supply Chain Security Act requirements.

Recent opportunities span Texas and a multistate region anchored in Minnesota and Oregon. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026, seeking offender specimen collection and drug testing services with proposals due July 23, 2026; the estimated contract value is $600,000 over two years with three optional one-year renewals, encompassing approximately 25,031 annual tests across five-panel and six-panel screens with staffing at two collection sites in Plano and McKinney. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription program capabilities prior to formal procurement. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, closing March 26, 2026, to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with evaluation weighted 75 percent on price competitiveness and the remainder on pricing format compliance, EDI capability, and administrative fee acceptance.